BioCentury
ARTICLE | Company News

AbbVie, Hayman Capital Management cancer news

October 26, 2015 7:00 AM UTC

The Patent Trial and Appeals Board (PTAB) of the U.S. Patent and Trademark Office (PTO) denied an inter partes review (IPR) petition from hedge fund manager Kyle Bass challenging a patent covering AbbVie’s Imbruvica ibrutinib.

The petition challenged U.S. Patent No. 8,754,090, which is one of 12 Orange Book-listed patents covering Imbruvica and expires June 3, 2031. PTAB said the petition did not sufficiently establish that a ClinicalTrials.gov webpage describing a Phase I trial of Imbruvica represented prior art that was available publicly by a specific date, and said the petition’s assertion that the patent was unpatentable due to obviousness relied on the webpage. PTAB also dismissed as moot a motion for sanctions by the patent owner alleging that Bass abused the IPR process. ...